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Abstract
Background: Here we study the effect of type 2 diabetes (T2DM) on bone cell precursors, turnover and cytokines
involved in the control of bone cell formation and activity.
Methods: We enrolled in the study 21 T2DM women and 21 non diabetic controls matched for age and body
mass index (BMI). In each subject we measured bone cell precursors, Receptor Activator of Nuclear Factor κB
(RANKL), Osteoprotegerin (OPG), Sclerostin (SCL) and Dickoppf-1 (DKK-1) as cytokines involved in the control
of osteoblast and osteoclast formation and activity, bone density (BMD) and quality trough trabecular bone
score (TBS) and bone turnover. T2DM patients and controls were compared for the analyzed variables by one
way ANOVA for Gaussian ones and by Mann-Whitney or Kruskal-Wallis test for non-Gaussian variables.
Results: RANKL was decreased and DKK-1 increased in T2DM. Accordingly, patients with T2DM have lower
bone turnover compared to controls. BMD and TBS were not significantly different from healthy controls.
Bone precursor cells were more immature in T2DM. However the number of osteoclast precursors was increased and
that of osteoblasts decreased.
Conclusions: Patients with T2DM have more immature bone cells precursors, with increased number of osteoclasts
and decreased osteoblasts, confirming low bone turnover and reduced cytokines such as RANKL and DKK-1. BMD and
TBS are not significantly altered in T2DM although, in contrast with other studies, this may be due to the match of
patients and controls for BMI rather than age.
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Background
Type 2 diabetes mellitus (T2DM) increases the risk of fra-
gility fractures [1], even though it is often associated with
increased bone density [1, 2]. T2DM has been associated
with poor bone quality [3] and this may lead to increased
fracture risk. Nevertheless, how T2DM affects bone is still
controversial. Several mechanisms may be involved, such
as direct effects of insulin resistance and hyperglycemia
on the bone and bone marrow microenvironment, ad-
vanced glycation end products of bone matrix proteins,
abnormal cytokine production, and impaired neuromus-
cular/skeletal interactions [4, 5]. Obesity associated with
T2DM may be a confounder due to its controversial effect
on bone per se (see Dolan et al., 2017 for a comprehensive
review) [6]. Several studies suggest that obesity protects
against bone loss in diabetic patients [7–9]. Moreover, re-
cent data suggest that obesity, regardless of the presence
of T2DM, is associated with a favorable bone microarchi-
tecture and greater bone strength at the distal radius and
distal tibia [10]. Serum markers of bone formation such as
osteocalcin (OCN) and amino-terminal propeptide of pro-
collagen type 1 (P1NP) have been found decreased in
T2DM patients [11–13], supporting the hypothesis that
bone formation is lower than in controls. Also bone re-
sorption has been found reduced in T2DM by some au-
thors [11, 14], however this data has not been confirmed
by others [15]. T2DM may affect bone metabolism influ-
encing osteoblast (OB) and osteoclast (OC) formation and
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activity by altering the cytokines involved in these pro-
cesses other than having direct toxic effect on bone cells.
OB formation and activity are mainly induced by the
activation of the Wnt pathway, two of the most studied in-
hibitors of this pathway being sclerostin (SCL) and
Dickoppf-1 (DKK-1) [16]. Otherwise, osteoclast formation
and activity are mainly regulated by the Receptor Activa-
tor of Nuclear Factor κB (RANKL), its receptor (RANK)
and its decoy receptor Osteoprotegerin (OPG) [17].
In vitro, in animal models and in humans it has been
demonstrated that hyperglycemia increases the level of
SCL [18–20] and DKK-1 [21–23], and that these cyto-
kines blunt osteoblast formation and activity. As regards
the RANKL/RANK/OPG pathway, this has been studied
mainly in relation to cardiovascular damage and vascular
calcification in T2DM [24]. Nowadays there are no hu-
man data on the relation between the cytokines involved
in the control of bone cells and bone cell precursors in
patients affected by T2DM. In this paper we show the
effect of T2DM on bone turnover, bone precursors cells
and cytokines involved in bone turnover taking into ac-
count the confounding factor of obesity and age.
Methods
Study population
We performed a case-control study enrolling 42 subjects,
21 women affected by T2DM and 21 non diabetic controls.
Patients and controls had been in spontaneous menopause
for, at least, one year. T2DM patients were matched with
controls for Body Mass Index (BMI) ± 2 SD and age ±
5 years. Screening for micro-and macrovascular complica-
tions of diabetes was done yearly. Retinopathy was investi-
gated by 45° digital retinal photography and graded
according to the American Academy of Ophthalmology
Simplified Classification [25]. Nephropathy was screened
for by measuring albumin excretion rate and serum creatin-
ine. Neuropathy was assessed according to the San Antonio
Consensus [26]. Large vessel disease was screened for by
examining peripheral pulses and history of coronary or per-
ipheral artery disease. None of the T2DM patients included
were affected by renal or macro-vascular complications, 4
were affected by retinopathy (19%). Of these patients,1 was
also affected by neuropathy, and another 5 only had neur-
opathy (23.8%). (Table 1 shows the clinical characteristics
of patients and controls). Five patients (23.8%) were treated
by insulin, 11 by metformin and five by DPP4 inhibitors.
T2DM patients were recruited from the outpatient
diabetes clinic of Medicina Interna 1 U. In Italy diabetic
patients are managed by general practitioners and period-
ically referred to specialist centers to evaluate their disease
state, hence the enrollment of patients from a tertiary re-
ferral center did not bias our results. Inclusion criteria for
patients were:female genderin post-menopausal period
and diagnosis of T2DM.
Exclusion criteria were: mental inability to sign the in-
formed consent; known secondary osteoporosis; treatment
with drugs active on bone turnover within the previous
six months including: biphosphonates, strontium ranelate,
parathyroid hormone, thyroid hormones, raloxifene,
denosumab, corticosteroids, estrogen, oral anticoagulants,
calcium and vitamin D andimmunosuppressant (as cyclo-
sporine, azathioprine) within the previous year; diagnosis
of type 1 diabetes; use of thiazolidinediones; history of
cancer; liver disease, kidney failure (stage II or higher);
malabsorption; hyperthyroidism.
Glycemic control in patients was measured by
Hemoglobin A1C (HbA1C) with high performance li-
quid chromatography (HPLC), the mean level was 57
± 8.1 mmol/mol.
Controls were recruited from the general population
starting from the database used for our previous study, fully
described elsewhere [27]. Briefly, controls were enrolled
from the general practitioner lists amongst non-diabetic
women without diseases active on bone metabolism,
matched for age and BMI to T2DM patients, as previously
described. Exclusion criteria were the same used for the pa-
tients. The whole population was Caucasian.
Clinical evaluation of bone health
An accurate medical history, including the presence of
fragility fractures, and physical examination was col-
lected in all women. A bone scan was performed with a
Hologic QDR 4500 X-ray densitometer to measure bone
mineral density (BMD), both at lumbar spine and femur,
and to evaluate the presence of vertebral fractures by
morphometric DXA analyses. The spinal deformity
Table 1 Characteristics of subjects
Patients (21) Controls(21) P value
Age (yrs) 71 ± 6 70 ± 6 –
Post-menopausalperiod (yrs) 22 ± 9 21 ± 7 NS
DMduration (yrs) 16 ± 2 – –
HbA1C (mmol/mol) 57 ± 8.1 – –
DM complications (%) 42.9% – –
Retinopathy (%) 14.3% – –
Neuropathy + retinopathy (%) 4.8% – –
Neuropathy (%) 23.8% – –
Insulin treatment (%) 23.8%
Metformin treatment (%) 52.4%
DPP4 inhibitors treatment (%) 23.8%
Waist/hip ratio 0.92 (0.88–0.96) 0.88 (0.84–0.94) NS
Fat mass (%) 39.4 (36.1–41.1) 39.1 (34.1–42.3) NS
BMI (Kg/m2) 29 ± 5 29 ± 5 –
Data depicted are mean ± SD for Gaussian variables and median with 25°
and 75° percentiles for non-Gaussian variables, non-continuous variables
are shown percentage. Statistical differences were analyzed by using
ANOVA one-way or Mann-Whitney U test
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index (SDI) [28] was calculated on DXA morphometry.
Bone texture was analyzed by trabecular bone score
(TBS) at lumbar vertebrae from DXA images with a ded-
icated software (TBS iNsight, Medimaps Group SA,
Pessac, France). TBS is a textural index that evaluates
pixel gray-level variations in the lumbar spine DXA
image, providing an indirect index of trabecular micro-
architecture. TBS is not a direct physical measurement
of bone microarchitecture, but rather an overall score
computed by the projection of the 3D structure onto a
2D plane that provides an indirect estimation of bone
microarchitecture from spine DXA images [29].
Bone turnover markers, cytokines and bone cells precursors
Markers of bone formation, OCN (Life Technologies
Corp, Frederick, MD), P1NP (USCN, Life Science Inc.
Houston, TX), and of bone resorption serum Tartrate
Resistant Acid Phosphatase 5b (TRAP5b, Quidel, San
Diego, CA) were measured by ELISA.
RANKL (Biovendor Research and Diagnostic Prod-
ucts, BRNO, Czech Republic), OPG (R&D Systems Inc.,
Minneapolis, USA), SCL (R&D Systems Inc., Minneapolis,
USA) and DKK-1 (R&D Systems Inc., Minneapolis, USA)
were also measured by ELISA.
To evaluate the role of circulating OC and OB precur-
sors in T2DM, we measured them in peripheral blood
mononuclear cells (PBMCs) separated by Ficoll-Paque
technique [30]. Briefly, OC precursors were evaluated by
staining PBMCs with fluorescein (FITC, supplied by B&D)
conjugated anti-vitronectin receptor (VNR), phycoerythrin
(PE, supplied by B&D) conjugated anti-CD14 and allophy-
cocyanin (APC, supplied by B&D) conjugated anti-CD11b
mAb, or with the corresponding isotype control, followed
by incubation at 4 °C for 30 min as previously described
[30]. Triple-positive cells (CD14+/CD11b+/VNR+) were
regarded as osteoclast precursors, according to the litera-
ture [30, 31]. OB precursors were evaluated by staining
PBMCs with FITC conjugated anti-CD15 (in order to ex-
clude granulocytes expressing alkaline phosphatase, sup-
plied by e-Bioscience), APC conjugated anti-alkaline
phosphatase (ALP, supplied by R&D System Inc), PE con-
jugated anti-OCN (supplied by R&D System Inc), or with
the corresponding isotype control, followed by incubation
at 4 °C for 30 min as previously described [30–32].
CD15-/ALP+/OCN+ cells were regarded as osteoblast
precursors according to the literature [30–32]. Membrane
antigen expression was analyzed with the CellQuest soft-
ware (Becton Dickinson & Co).
Fat mass
In order to compare patients and controls for body
fat mass and distribution, body fat was assessed by
plicometry (Mahr GMBH Esslingen). The Pollock, Schmidt
and Jackson’s formula was used on three sites (triceps,
subscapular and abdomen) to calculate fat percentage [33].
In order to calculate BMI the women were weighted with a
precision scale and their height recorded with a wall-
mounted altimeter. BMI was measured as weight in Kg/
squared height in meters, to evaluate fat distribution the
waist/hip ratio was measured.
Statistical analyses
The sample size was calculated to provide an 80% power
(p < 0.05) to detect a 2-fold difference in SCL and
DKK-1 in T2DM compared to healthy controls. The
2-fold difference was chosen based on previous papers
[18–23]. In order to correctly weight the other data ob-
tained the sample calculated post-hoc to evaluate differ-
ences in BMD to provide an 80% power (p < 0.05) to
detect a 0.140 g difference in BMD in T2DM compared
to healthy controls48 patients per group will be neces-
sary. The 0.140 g difference was chosen based on previ-
ous papers [1, 2]. The sample size needed to evaluate
differences in TBS to provide an 80% power (p < 0.05) to
detect a 0.05difference in TBS in T2DM compared to
healthy controls 100 patients per group will be neces-
sary. The 0.05 difference was chosen on the basis of a
previous paper [34]. The sample size needed to evaluate
differences in bone turnover and in particular in P1NP
to provide an 80% power (p < 0.05) to detect a 8 ng/mL
difference in T2DM compared to healthy controls 33 pa-
tients per group will be necessary. The 8 ng/mL differ-
ence was chosen on the basis of previous paper [35].
T2DM patients and controls were compared by one-way
ANOVA for Gaussian variables, by Mann-Whitney or
Kruskal-Wallis test for non-Gaussian variables. Gaussian
distribution was evaluated by kurtosis test. Gaussian
variables were correlated by Pearson’s coefficient, non-
Gaussian with Spearman correlation. Data were tested for
outliers with the ROUT method, no outliers were identify
and removed from the analyses. Statistics were performed
by means of SPSS 24.0 for windows, Graph Pad Prism 7.0
for windows was used to drawn the graphs. P values were
considered significant if lower than 0.05.
Results
T2DM affects bone precursors cell
To evaluate if T2DM affects circulating bone precursors
cells, we measured circulating OB and OC precursor
cells and cytokines involved in osteoclastogenesis, os-
teoblastogenesis and in the regulation of bone turn-
over. We observed a significant reduction of circulating
OB precursors cells in T2DM patients compared to
controls (Fig. 1a), whereas OC precursors are increased
(Fig. 1c). Both OC and OB precursors are more immature
in diabetic patients; in particular OBs express lower levels
of ALP and OCs express lower levels of VNR (Fig. 1b, d).
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Cytokines involved in the regulation of bone cells are
altered in T2DM patients: DKK-1 was increased in pa-
tients compared to controls (p = 0.04), whereas RANKL
was decreased in T2DM (p = 0.0362). DKK-1 was 1824 pg/
mL (1345–2572 interquartile range (IQR)) in T2DM versus
1526 pg/mL (963.2–1792 IQR) in the control group;
RANKL was 3590 pg/mL (1434–7154 IQR) in T2DM ver-
sus 5018 pg/mL (2632–9343 IQR) in the control group
(Fig. 2a, c). OPG was not significantly altered 965.2 pg/mL
(759.1-1346IQR) in T2DM versus 938 pg/mL (783–1207
IQR) in the control group (Fig. 2b). SCL was undetectable
in the majority of both patients’ and controls’ sera 561.3 ±
73.4 pg/mL in T2DM versus 309.8 ± 31 pg/mL (Fig. 2d). In
three T2DM and 5 controls SCL was detectable in the
serum, in those subjects bone formation measured by
P1NP was significantly lower (12,420.6 ± 6706.1 vs 24,025.2
± 992.9, p = 0.003), no other differences in the tested
variables were detectable. The increased level of SCL
may be related to decreased bone formation measured
by P1NP.
Fig. 1 Dot plots show bone cell precursors in peripheral blood in T2DM patients and controls. Panel a: OB precursor cells; Panel b: ALP expression by
OB precursor cells as measured by flow cytometry; Panel c: OC precursor cells; Panel d: VNR expression by OC precursor cells as measured by flow
cytometry. P value was calculated with by one way ANOVA and is shown in the graph when significant
Fig. 2 Graphs show cytokines involved in the control of bone cells formation and activity in T2DM patients and controls. Panel a: RANKL; Panel b:
OPG; Panel c: DKK-1. Panel d: SCL. Box and whiskers plot displays median, the first and third quartiles, and the minimum and maximum of the data.
P value was calculated with by Mann-Whitney test and is shown in the graph when significant
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Age per se is weakly correlated with RANKL (R = 0.32,
p = 0.047) and with OB precursors maturation (R = −
0.384, p = 0.048). Post-menopausal state is directly corre-
lated with RANKL (R = 0.323, P = 0.045). Other parame-
ters are not influenced by age, post-menopausal state or
by BMI.
Glycemic control measured by HbA1C did not correl-
ate with bone cell precursor percentage and maturation,
nor with cytokines involved in the control of bone
turnover. There were no significant differences in the
parameters analyzed in patients with or without diabetic
complications and between patients taking different
anti-hyperglycaemic drugs (data not shown).
Bone metabolism is impaired in T2DM patients
BMD measured at lumbar spine, femoral neck and total
femur was not significantly different between patients
and controls; even though lumbar BMD was, on average,
higher in T2DM than in controls. Bone structure mea-
sured by TBS, as well as SDI, were not altered in dia-
betic patients compared to controls (Table 2).
Obesity influences bone per se as there were signifi-
cant correlations between BMI, BMD and TBS, the dis-
tribution of fat influenced only TBS (Table 3). Bone
formation measured by P1NP as well as bone resorption
measured by TRAP5b were significantly decreased in
T2DM (Fig. 3). Glycemic control measured by HbA1C
influenced bone structure but not bone density (Table 3).
As regards bone turnover markers, HbA1C was inversely
correlated with bone formation measured by OCN (R = −
0.59, p = 0.005).
Discussion
The detrimental effect of T2DM on bone is well estab-
lished [1, 2], but the possible mechanisms through which
this happens have not been clearly elucidated. Here we
evaluated the effect of T2DM on bone precursor cells
and cytokines in patients and controls matched for BMI
as well as age. One of the most confounding factor in
the evaluation of diabetes effect on bone health is obes-
ity, which is often associated with T2DM and has con-
troversial effect on bone metabolism and fracture risk
per se. Some studies suggest that obese subjects have a
lower risk of proximal femur and vertebral fracture
compared to adults with normal BMI [36, 37]. However
the risk of fracture in obese subjects is variable at differ-
ent skeletal sites according to the difference in falling
mechanisms in these patients; in particular the risk for
proximal humerus, upper leg and ankle fracture is
higher in obese than in non-obese adults [38]. Moreover,
increased fat mass could be detrimental to bone due to
increased inflammation and production of adipokines
that affect bone turnover [39, 40]. For these reasons, we
enclosed in this study controls matched with patients for
BMI as well as for age. The use of obese controls may
explain why, differently from other studies, we did not
find significant differences in bone microarchitecture
measured by TBS between T2DM patients and controls.
Although our study was not powered to measure differ-
ences in TBS [3, 41], our data show that obesity is in-
versely correlated with bone quality measured by TBS.
Here we show that osteoblast precursors cells are de-
creased and more immature according with decreased
bone formation and increased DKK-1, whereas OC pre-
cursors are increased in the peripheral blood of T2DM
patients. Data on OCs seem to be in contrast with de-
creased bone resorption in patients. However, it should
be underlined that these are immature cells, which may
not be able to home in bone microenvironment. Low
RANKL levels in patients may explain the low grade of
OCs maturation and decreased bone resorption.
This is the first study to evaluate bone cell precursors
in the peripheral blood of diabetic patients.Previous data
ina diabetic mouse model suggested reduced osteoclast
and osteoblast formation in bone microenvironment
[42]. An elegant in vitro study suggests that osteoclasto-
genesis mediated by RANKL is impaired in the presence
of high glucose levels [43].
The increase in DKK-1, a well-known negative regula-
tor of bone formation, may explain the decrease in bone
formation in T2DM and confirms previous reports
[18–20]. On the contrary, SCL was mostly undetectablein
our cohort of patients. In the patients with detectable level
Table 2 Bone health in T2DM patients and controls
T2DM patients (21) Controls (21) P value
Lumbar BMD (g/cm2) 0.97 ± 0.16 0.92 ± 0.15 0.059
FemoralBMD (g/cm2) 0.71 ± 0.12 0.69 ± 0.11 0.275
SDI 0 (0–1) 0 (0–1) 0.982
TBS 0.926 (0.799–1.027) 0.965 (0.766–1.051) 0.875
Data depicted are mean ± SD for Gaussian variables and median with 25° and
75° percentiles for non-Gaussian variables. Statistical differences are analyzed
by using ANOVA one-way or Mann-Whitney U test
Table 3 Correlations between bone density and structure, obesity
and glycemic control
BMI Fat mass Waist/hip HbA1C
Lumbar BMD r 0.23 0.84 0.91 −0.35
p 0.005 0.338 0.276 0.286
Femoral BMD r 0.27 0.154 0.10 −0.092
p 0.001 0.078 0.904 0.701
TBS r −0.319 −0.36 −0.34 − 0.55
p < 0.0001 0.693 < 0.0001 0.016
Pearson’ coefficient correlations between BMD measured at lumbar spine and
at femoral neck and BMI, Fat mass % and waist/hip ratio in the whole population
under study, TBS was correlated by Spearman coefficient. Correlations between
bone parameters and HbA1C were run only in T2DM patients. Significant values
are in bold
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we found a decreased bone formation without any other
differences in the variables measured. Several studies in-
vestigated the levels of SCL in diabetic patients reporting
conflicting results. Gennari et al. [44] showed increased
levels of SCL in T2DM, but not in Type 1 diabetes melli-
tus (T1DM); other studies reported increased SCL in
T2DM [45–47]. A recent study on post-menopausal
women showed no difference between diabetic and
non-diabetic patients in SCL levels [48]. In our study we
evaluated only post-menopausal obese subjects, and this
may be the reason why we achieved different results from
other studies which included younger, leaner populations,
also including men. Glycemic control, the use of different
anti-hyperglycaemic drugs and the presence of diabetic
complications did not appear to bias our results. Poor gly-
cemic control may influence the levels and activity of cyto-
kines active on bone turnover, some studies demonstrated
that OPG is increased in T2DM and T1DM patients re-
gardless to their glycemic control [49, 50], this finding is
controversial as another study shows a reduction in OPG
in T1DM patients [51], here we do not find any significant
increase in OPG regardless to glycemic control. RANKL
levels seem not to be influenced by glycemic control as
shown by Lappin and colleagues [49], we found a decreased
RANKL level without any correlation with glycemic con-
trol. SCL levels were not studied in relation with glycemic
controls in previous studies [20, 44] here we do not find
any relationship between glycemic control and SCL.
As regards clinical evaluation of bone health, we did
not find a significant increase in BMD in T2DM com-
pared to controls, in contrast to previous results [1, 2].
However, our cohort was small and the use of obese
controls may have influenced this result as BMI per se,
regardless of T2DM, is directly correlated with BMD
both at lumbar spine and femoral neck.
As regards bone turnover, we found a significant de-
crease in bone formation and bone resorption in T2DM,
confirming other studies [22, 35, 52].
The study was not powered to detect differences in
fracture prevalence, hence the similar SDI between
T2DM and controls may be due to chance. Age was
weakly correlated with RANKL, as expected, and –
interestingly – inversely correlated with OB precursor
maturation. Use of controls matched with patients for
age and BMI excludes this as a confounding factor.
Our study has several strengths and limitations. The
analyses of bone turnover and related controlling cyto-
kines was performed in well-characterized cohorts of
patients and matched controls. This is the first study
evaluating the role of bone cell precursors in T2DM.
The significance of our findings may be limited by the
small sample size and lack of measurement of parame-
ters related to inflammation and adipocytokines produc-
tion, some of the results reported may be flawed by the
insufficient power.
Conclusion
We show that bone precursor cells are affected by
T2DM and, in particular there was a reduction of OB
precursors and an increase in OC precursors. Both cell
types appear to be more immature in T2DM, and this
could be explained by increased levels of DKK-1 and de-
creased levels of RANKL.
Fig. 3 Graphs show bone turnover markers in T2DM patients and controls. Panel a: the bone formation marker P1NP; Panel b: the bone formation
marker OCN; Panel c: the bone resorption marker TRAP5b. Box and whiskers plot displays median, the first and third quartiles, and the minimum and
maximum of the data. P value was calculated with by Mann-Whitney test and is shown in the graph when significant
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